Editorial comment
Guidelines on hyponatremia that not always guide
Guías ¿que no guían? Sobre hiponatremia
Read
10763
Timeswas read the article
3288
Total PDF
7475
Total HTML
Share statistics
array:24 [ "pii" => "S2013251417301268" "issn" => "20132514" "doi" => "10.1016/j.nefroe.2017.03.007" "estado" => "S300" "fechaPublicacion" => "2017-07-01" "aid" => "353" "copyright" => "Sociedad Española de Nefrología" "copyrightAnyo" => "2017" "documento" => "article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "sco" "cita" => "Nefrologia (English Version). 2017;37:357-9" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 4238 "formatos" => array:3 [ "EPUB" => 310 "HTML" => 3022 "PDF" => 906 ] ] "Traduccion" => array:1 [ "es" => array:20 [ "pii" => "S0211699517300590" "issn" => "02116995" "doi" => "10.1016/j.nefro.2017.03.001" "estado" => "S300" "fechaPublicacion" => "2017-07-01" "aid" => "353" "copyright" => "Sociedad Española de Nefrología" "documento" => "article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "sco" "cita" => "Nefrologia. 2017;37:357-9" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 7042 "formatos" => array:3 [ "EPUB" => 350 "HTML" => 5230 "PDF" => 1462 ] ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Comentario editorial</span>" "titulo" => "Guías ¿que no guían? Sobre hiponatremia" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "357" "paginaFinal" => "359" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Guidelines on hyponatremia that not always guide" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Roberto Alcázar, Alberto Tejedor" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Roberto" "apellidos" => "Alcázar" ] 1 => array:2 [ "nombre" => "Alberto" "apellidos" => "Tejedor" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2013251417301268" "doi" => "10.1016/j.nefroe.2017.03.007" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2013251417301268?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0211699517300590?idApp=UINPBA000064" "url" => "/02116995/0000003700000004/v1_201707260022/S0211699517300590/v1_201707260022/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S2013251417301153" "issn" => "20132514" "doi" => "10.1016/j.nefroe.2017.06.005" "estado" => "S300" "fechaPublicacion" => "2017-07-01" "aid" => "326" "copyright" => "Sociedad Española de Nefrología" "documento" => "article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2017;37:381-8" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 4261 "formatos" => array:3 [ "EPUB" => 282 "HTML" => 2156 "PDF" => 1823 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original</span>" "titulo" => "Serum ICAM-1 level and ICAM-1 gene 1462A>G (K469E) polimorphism on microalbuminuria in nondiabetic, nonhypertensive and normolipidemic obese patients: Genetical background of microalbuminuria in obesity" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "381" "paginaFinal" => "388" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Polimorfismo 1462A>G (K469E) del gen <span class="elsevierStyleItalic">ICAM-1</span> y nivel sérico de ICAM-1 en la oligoalbuminuria de pacientes obesos no diabéticos, no hipertensos y normolipidémicos: acervo genético de la oligoalbuminuria en la obesidad" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 583 "Ancho" => 1622 "Tamanyo" => 65016 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0080" class="elsevierStyleSimplePara elsevierViewall">2% agarose gel electrophoresis stained with ethidium bromide showing the PCR-RFLP analysis of the ICAM-1. Lanes M: DNA marker. Lanes 1, 2: AA allelic polymorphism; Lane 3, 4: AG allelic polymorphism; Lane 5, 6: GG allelic polymorphism.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Ahmet Engin Atay, Bennur Esen, Halit Akbas, Emel Saglam Gokmen, Saadet Pilten, Hale Guler, Dilek Gogas Yavuz" "autores" => array:7 [ 0 => array:2 [ "nombre" => "Ahmet Engin" "apellidos" => "Atay" ] 1 => array:2 [ "nombre" => "Bennur" "apellidos" => "Esen" ] 2 => array:2 [ "nombre" => "Halit" "apellidos" => "Akbas" ] 3 => array:2 [ "nombre" => "Emel Saglam" "apellidos" => "Gokmen" ] 4 => array:2 [ "nombre" => "Saadet" "apellidos" => "Pilten" ] 5 => array:2 [ "nombre" => "Hale" "apellidos" => "Guler" ] 6 => array:2 [ "nombre" => "Dilek Gogas" "apellidos" => "Yavuz" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2013251417301153?idApp=UINPBA000064" "url" => "/20132514/0000003700000004/v1_201708310023/S2013251417301153/v1_201708310023/en/main.assets" ] "en" => array:14 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial comment</span>" "titulo" => "Guidelines on hyponatremia that not always guide" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "357" "paginaFinal" => "359" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Roberto Alcázar, Alberto Tejedor" "autores" => array:2 [ 0 => array:4 [ "nombre" => "Roberto" "apellidos" => "Alcázar" "email" => array:1 [ 0 => "ralcazar@senefro.org" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Alberto" "apellidos" => "Tejedor" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Servicio de Nefrología, Hospital Universitario Infanta Leonor, Madrid, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Servicio de Nefrología, Hospital Universitario Gregorio Marañón, Madrid, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "<span class="elsevierStyleItalic">Corresponding author</span>." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Guías ¿que no guían? Sobre hiponatremia" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Clinical practice guidelines (CPG) are one of the most commonly used tools to ensure that at any given time the best available evidence is transferred into clinical practice. Unlike expert consensus documents, they are a set of recommendations based on a systematic review and critical reading of all the available evidence on a particular subject. The ultimate aims of CPG are to facilitate decision-making for the healthcare professional, optimise patient care and reduce variability in clinical practice.</p><p id="par0010" class="elsevierStylePara elsevierViewall">The utility of CPG for improving clinical outcomes is widely recognised, although they have both intrinsic and extrinsic limitations.<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">1</span></a> The methodology problems have largely been corrected thanks to the periodic recommendations of the AGREE project (<a href="http://www.agreetrust.org/agree-research-projects/">http://www.agreetrust.org/agree-research-projects/</a>) and, at a more local level, the recommendations of the Spanish National Health Service through the Healthcare Guide portal (<a href="http://portal.guiasalud.es/">http://portal.guiasalud.es</a>).</p><p id="par0015" class="elsevierStylePara elsevierViewall">Probably one of the main limitations, especially in nephrology, is the lack of sufficient evidence to be able to provide sound recommendations. Moreover, both the number and quality of controlled studies in nephrology are well below those in other specialist areas.<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">2</span></a> If there are either no clinical trials or they are of poor quality, the weight of the evidence in CPG recommendations is diluted, and more prominence is given to the opinions of the “panel of experts” who draft the guidelines.</p><p id="par0020" class="elsevierStylePara elsevierViewall">The current issue of <span class="elsevierStyleSmallCaps">Nefrología</span>has published the abbreviated Spanish translation of the Clinical Practice Guideline on Diagnosis and Treatment of Hyponatraemia, developed by the European Society of Intensive Care Medicine (ESICM), the European Society of Endocrinology (ESE) and the European Renal Association – European Association for Dialysis and Transplantation (ERA-EDTA), represented by European Renal Best Practice (ERBP).<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">3</span></a> This is a set of CPG put together according to the methodology proposed in AGREEII and published 2 years ago<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">4</span></a> in an attempt to establish recommendations that can be easily accepted by the different specialists dealing with the diagnosis and treatment of hyponatraemia in their different clinical settings.</p><p id="par0025" class="elsevierStylePara elsevierViewall">The European CPG came about as a result of the increased number of publications on hyponatraemia during the recent years, and the proliferation of documents on its management and treatment. This, in turn, is a direct consequence of the appearance in the market of vapants, aquaretic drugs for the treatment of hyponatraemia associated with SIADH (European Medicines Agency indication) and hypervolaemic hyponatraemia (FDA indication, added to that for SIADH). Any novel drug is an incentive for research on the drug itself and the diseases in which it is indicated. It is not surprising, therefore, that there has been a proliferation of different guidelines and documents on this disease. Among them, we would highlight the Spanish expert consensus on hyponatraemia,<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">5</span></a> the international consensus on hyponatraemia<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">6</span></a> and the European CPG summarised in this issue of <span class="elsevierStyleSmallCaps">Nefrología</span>.<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">4</span></a> The journal <span class="elsevierStyleSmallCaps">Nefrología</span>also discussed the importance of hyponatraemia in a supplement published in 2017.<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">7</span></a> It should be noted that, in all these documents, most of the authors declared conflicts of interest with companies that market vaptans. Only for the European CPG funding was declared to be independent from the industry (funding was provided by the scientific societies involved).</p><p id="par0030" class="elsevierStylePara elsevierViewall">In all these documents, the main problem is the lack of evidence to support the recommendations. The fact is that for disorders of the internal environment, there is a well-recognised lack of clinical trials evaluating the efficacy of different interventions for correcting them. Most of the guidelines are based on clinical experience and the translation of pathophysiology into clinical practice. As a result, the quality of the evidence of nearly all the recommendations in the European CPG on hyponatraemia is D (very low).</p><p id="par0035" class="elsevierStylePara elsevierViewall">The combination of the lack of solid evidence and the need to give recommendations to other specialists besides nephrologists has stimulated nephrologist to generation of some statements about the European guidelines. Kidney specialists are very used to dealing with disorders of the body composition from basic concepts of renal physiology and pathophysiology. It is noticeable the absence of references to estimations of the sodium (Na), potassium (K), chlorine (Cl) and water balance, and the utility of electrolyte-free water clearance as tools to aid decision-making. The European CPG only mention symptoms, urinary osmolality (Osm<span class="elsevierStyleInf">u</span>) and Na<span class="elsevierStyleInf">u</span> if Osm<span class="elsevierStyleInf">u</span><span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>100<span class="elsevierStyleHsp" style=""></span>mOsm/kg. That is a very simplistic approach that can lead to misinterpretation. Thus, periodic monitoring of electrolyte-free water clearance by comparing Na<span class="elsevierStyleInf">p</span> with the sum of urinary cations (Na<span class="elsevierStyleInf">u</span><span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>K<span class="elsevierStyleInf">u</span>) allows us to estimate the capacity of the kidneys to excrete free water and anticipate the response to water restriction in the case of chronic non-hypovolaemic hyponatraemia and the tonicity of the fluid therapy administered.<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">8</span></a> It also makes it possible to anticipate recovery by the kidneys of the ability to remove free water and prevent rapid correction of hyponatraemia. An example of the utility of these calculations is shown in <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>. The clinical situations with the highest risk of rapid hyponatraemia correction are described in <a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>.</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><p id="par0040" class="elsevierStylePara elsevierViewall">Na<span class="elsevierStyleInf">u</span> is not always a good reflection of volaemia, however. In patients with volume depletion as a result of vomiting, the presence of organic anions such as HCO<span class="elsevierStyleInf">3</span><span class="elsevierStyleSup">−</span> is accompanied by Na, so the Na<span class="elsevierStyleInf">u</span> will be raised, but not the Cl<span class="elsevierStyleInf">u</span>.<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">9</span></a></p><p id="par0045" class="elsevierStylePara elsevierViewall">Only a holistic and individualised view of each patient, taking into account the contributions of active osmoles (including ions), both oral and parenteral, together with periodic monitoring of diuresis, blood ions in blood, and urine ions (Na, K, Cl) and osmolality will help provide clear guidance towards a diagnosis, optimise the treatment and anticipate possible complications resulting from inadequate correction of the hyponatraemia. Moreover, therapeutic decisions should be based on clinical and analytical progress, and not so much on an isolated determination of Nap; the consensus documents and the European CPG do not contemplate the analytical and biological variation inherent in measurements of Na.<a class="elsevierStyleCrossRef" href="#bib0105"><span class="elsevierStyleSup">10</span></a> An actual natraemia of 121<span class="elsevierStyleHsp" style=""></span>mEq/L may be reported by the laboratory in the interval 118–125<span class="elsevierStyleHsp" style=""></span>mEq/L, which represents the critical difference (reference change value, RCV) of the Nap measurement with a 95% confidence interval, reinforcing the need to monitor and assess the hyponatraemic patient holistically.</p><p id="par0050" class="elsevierStylePara elsevierViewall">Lastly, we would make two comments about the treatment. It is evident that hyponatraemia with moderate or severe symptoms benefits from treatment with hypertonic saline. A fixed therapeutic regimen is given using a solution (3% NaCl) which is not generally available in pharmacies, and it is not provided an easy “recipe” to prepare this hypertonic solution, as it is done in other documents.<a class="elsevierStyleCrossRefs" href="#bib0080"><span class="elsevierStyleSup">5,7</span></a> We personally prefer to provide this “recipe” (add 30<span class="elsevierStyleHsp" style=""></span>mL of 20% NaCl to 250<span class="elsevierStyleHsp" style=""></span>cc of 0.9% saline solution) and administer it according to the patient's estimated weight and the severity of their symptoms (0.5–2<span class="elsevierStyleHsp" style=""></span>mL/kg/h). The second is the recommendation against the use of vaptans in the treatment of chronic normovolaemic hyponatraemia with the absence or only mild symptoms. It is surprising that the only therapeutic strategy (tolvaptan) to have proven useful in the treatment of normovolaemic and hypervolaemic chronic hyponatraemia in controlled, randomised studies is excluded as a valid option in the European CPG, based on the fact that it could increase the risk of pontine myelinolysis given the risk of rapid correction of natraemia, even though this complication was not detected in the clinical trials.<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">11</span></a> However, they do recommend using oral urea, which has no clinical trials to support its utility and which, theoretically, could have the same risk of excessive correction as the vaptans.</p><p id="par0055" class="elsevierStylePara elsevierViewall">CPG are highly useful tools for ensuring the best available evidence is transferred into clinical practice. The translated version of the CPG on hyponatraemia in this issue of <span class="elsevierStyleSmallCaps">Nefrología</span> is undoubtedly a major effort to improve the therapeutic approach to hyponatraemia, and a reason for reflecting on the need to design studies in our speciality that not only improve and standardise the guidelines, but also the strength of the recommendations they contain. We encourage all nephrologists to read these European CPG with a critical and constructive eye. We hope that it serves as a stimulus for more in-depth investigation of the pathophysiology of hyponatraemia and the holistic management of this and other disorders of the internal environment.</p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Conflicts of interest</span><p id="par0060" class="elsevierStylePara elsevierViewall">R. Alcázar has received fees from Otsuka and Medical Nutrition for lectures. A. Tejedor has worked as a nephrology consultant for the Spanish Medicines Agency and the European Medicines Agency, and is a consultant for Otsuka.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0005" "titulo" => "Conflicts of interest" ] 1 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Alcázar R, Tejedor, A. Guías ¿que no guían? Sobre hiponatremia. Nefrología. 2017;37:357–359.</p>" ] ] "multimedia" => array:2 [ 0 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">A 79-year-old woman visits A&E for headache and cognitive impairment with drowsiness. Hypertension, diabetes on treatment with paroxetine, lisinopril and metformin. No apparent focal signs on neurological examination.</span> Tests show <span class="elsevierStyleItalic">blood glucose: 142</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">mg/dL; blood Cr: 0.9</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">mg/dL; Na: 114</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">mEq/L; K: 4.4</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">mEq/L; Osm</span><span class="elsevierStyleInf"><span class="elsevierStyleItalic">u</span></span><span class="elsevierStyleItalic">: 302</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">mOsm/kg; Na</span><span class="elsevierStyleInf"><span class="elsevierStyleItalic">u</span></span><span class="elsevierStyleItalic">: 62</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">mEq/L; K</span><span class="elsevierStyleInf"><span class="elsevierStyleItalic">u</span></span><span class="elsevierStyleItalic">: 58</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">mEq/L; Cl</span><span class="elsevierStyleInf"><span class="elsevierStyleItalic">u</span></span><span class="elsevierStyleItalic">: 99</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">mEq/L. Infusion started of 3% NaCl; 1</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">mL/kg/h.</span> 2<span class="elsevierStyleHsp" style=""></span>h later: <span class="elsevierStyleItalic">Na: 118</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">mEq/L diuresis 180</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">mL; Na</span><span class="elsevierStyleInf"><span class="elsevierStyleItalic">u</span></span><span class="elsevierStyleItalic">: 54</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">mEq/L; K</span><span class="elsevierStyleInf"><span class="elsevierStyleItalic">u</span></span><span class="elsevierStyleItalic">: 52</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">mEq/L.</span> 4<span class="elsevierStyleHsp" style=""></span>h later <span class="elsevierStyleItalic">(6</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">h from start): Na: 121</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">mEq/L; diuresis 210</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">mL; Osm</span><span class="elsevierStyleInf"><span class="elsevierStyleItalic">u</span></span><span class="elsevierStyleItalic">: 290</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">mOsm/kg; Na</span><span class="elsevierStyleInf"><span class="elsevierStyleItalic">u</span></span><span class="elsevierStyleItalic">: 52</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">mEq/L; K</span><span class="elsevierStyleInf"><span class="elsevierStyleItalic">u</span></span><span class="elsevierStyleItalic">: 50</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">mEq/L. Slight improvement in cognitive deterioration. Hypertonic saline infusion discontinued and started on diet with salt and fluid restriction of 500</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">mL/day. Paroxetine stopped.</span> At 24<span class="elsevierStyleHsp" style=""></span>h: <span class="elsevierStyleItalic">Na: 126</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">mEq/L; diuresis: 532</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">mL; Osm</span><span class="elsevierStyleInf"><span class="elsevierStyleItalic">u</span></span><span class="elsevierStyleItalic">: 280</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">mOsm/kg; Na</span><span class="elsevierStyleInf"><span class="elsevierStyleItalic">u</span></span><span class="elsevierStyleItalic">: 42</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">mEq/L; K</span><span class="elsevierStyleInf"><span class="elsevierStyleItalic">u</span></span><span class="elsevierStyleItalic">: 37</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">mEq/L. Restart salt-free diet salt and liberalise water intake, insisting that patient drink at least one litre of water.</span> At 24<span class="elsevierStyleHsp" style=""></span>h, <span class="elsevierStyleItalic">Na: 133</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">mEq/L; diuresis 1220</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">mL; Na</span><span class="elsevierStyleInf"><span class="elsevierStyleItalic">u</span></span><span class="elsevierStyleItalic">: 28</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">mEq/L; K</span><span class="elsevierStyleInf"><span class="elsevierStyleItalic">u</span></span><span class="elsevierStyleItalic">: 44</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">mEq/L. Improvement of neurological status compared to baseline situation.</span> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">This example of antidepressant-induced syndrome of inappropriate antidiuretic hormone secretion (serotonin-uptake inhibitors) is an example of how ions, not urinary osmolality, allow us to detect how renal diluting capacity is being restored (the sum of urinary cations [Na<span class="elsevierStyleInf">u</span><span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>K<span class="elsevierStyleInf">u</span>] decreases progressively, indicating increasing clearance of electrolyte-free water), which allows early suspension of water restriction and avoids faster than desired corrections of natraemia. The causes of hyponatraemia with risk of rapid correction are shown in <a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>. \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1502134.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Example of the utility of urine electrolyte monitoring in the treatment of hyponatraemia.</p>" ] ] 1 => array:8 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at2" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Cause \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Mechanism \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Thiazides in elderly patients \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Stopping the thiazide restores renal diluting capacity \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Serotonin reuptake inhibitors \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Disappearance of drug-induced SIADH \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Adrenal insufficiency \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">The administration of saline and cortisol reduces the release of ADH and restores renal diluting capacity \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Hypoxaemia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">The disappearance of hypoxaemia decreases non-osmotic release of ADH \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Nausea, surgery, pain, stress \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Resolving these issues removes the non-osmotic ADH release stimulus \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Hypovolaemia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Restoration of volaemia stops baroreceptor-mediated vasopressin secretion \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Beer drinkers \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Intake of solutes restores renal diluting capacity \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Vasopressin \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Stopping the vasopressin restores renal diluting capacity \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1502133.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Causes of hyponatraemia with risk of rapid correction of the natraemia during treatment.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:11 [ 0 => array:3 [ "identificador" => "bib0060" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Contribuciones de las guías clínicas a la mejora de los resultados" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "E. Parra" 1 => "F. Álvarez-Ude" 2 => "D. Arenas" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Nefrología Sup Ext" "fecha" => "2010" "volumen" => "1" "paginaInicial" => "7" "paginaFinal" => "15" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0065" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The number, quality, and coverage of randomized controlled trials in nephrology" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "G.F. Strippoli" 1 => "J.C. Craig" 2 => "F.P. Schena" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Am Soc Nephrol" "fecha" => "2004" "volumen" => "15" "paginaInicial" => "411" "paginaFinal" => "419" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14747388" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0070" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Guía de práctica clínica sobre el diagnóstico y tratamiento de la hiponatremia" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G. Spasovski" 1 => "R. Vanholder" 2 => "B. Allolio" 3 => "D. Annane" 4 => "S. Ball" 5 => "D. Bichet" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "Nefrología" "fecha" => "2017" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11217655" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0075" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical practice guideline on diagnosis and treatment of hyponatraemia" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G. Spasovski" 1 => "R. Vanholder" 2 => "B. Allolio" 3 => "D. Annane" 4 => "S. Ball" 5 => "D. Bichet" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Nephrol Dial Transpl" "fecha" => "2014" "volumen" => "29" "numero" => "Suppl. 2" "paginaInicial" => "i1" "paginaFinal" => "i39" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0080" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "El tratamiento de la hiponatremia secundaria al síndrome de secreción inadecuada de la hormona antidiurética" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "I. Runkle" 1 => "C. Villabona" 2 => "A. Navarro" 3 => "A. Pose" 4 => "F. Formiga" 5 => "A. Tejedor" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Med Clin (Barc)" "fecha" => "2013" "volumen" => "141" "paginaInicial" => "507e1" "paginaFinal" => "507e10" ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0085" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Diagnosis, evaluation and treatment of hyponatremia: expert panel recommendations" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.G. Verbalis" 1 => "S.R. Goldsmith" 2 => "A. Greenberg" 3 => "C. Korzelius" 4 => "R.W. Schrier" 5 => "R.H. Sterns" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.amjmed.2013.07.006" "Revista" => array:7 [ "tituloSerie" => "Am J Med" "fecha" => "2013" "volumen" => "126" "numero" => "Suppl. 1" "paginaInicial" => "s1" "paginaFinal" => "s42" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24074529" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0090" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:1 [ "titulo" => "Actualización en hiponatremias" ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Nefrología Sup Ext" "fecha" => "2011" "volumen" => "2" "paginaInicial" => "1" "paginaFinal" => "83" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0095" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The urine/plasma electrolyte ratio: a predictive guide to water restriction" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "H. Furst" 1 => "K.R. Hallows" 2 => "J. Post" 3 => "S. Chen" 4 => "W. Kotzker" 5 => "S. Goldfarb" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Am J Med Sci" "fecha" => "2000" "volumen" => "319" "paginaInicial" => "240" "paginaFinal" => "244" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10768609" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0100" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Diagnostic value of urinary sodium, chloride, urea, and flow" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "R.W. Schrier" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1681/ASN.2010121289" "Revista" => array:6 [ "tituloSerie" => "J Am Soc Nephrol" "fecha" => "2011" "volumen" => "22" "paginaInicial" => "1610" "paginaFinal" => "1613" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21852582" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0105" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Reference change values for sodium are ignored by the American and European treatment guidelines for hyponatremia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "W.P. Tormey" 1 => "M. Carney" 2 => "M. Cuesta" 3 => "S. Sreenan" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1373/clinchem.2015.242602" "Revista" => array:7 [ "tituloSerie" => "Clin Chem" "fecha" => "2015" "volumen" => "61" "paginaInicial" => "1430" "paginaFinal" => "1432" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26152751" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0022534709017479" "estado" => "S300" "issn" => "00225347" ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0110" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The clinical practice guideline on diagnosis and treatment of hyponatraemia: a response from Otsuka pharmaceutical Europe Ltd" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "M. Avila" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1530/EJE-14-0392" "Revista" => array:6 [ "tituloSerie" => "Eur J Endocrinol" "fecha" => "2014" "volumen" => "171" "paginaInicial" => "L1" "paginaFinal" => "L3" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24939859" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/20132514/0000003700000004/v1_201708310023/S2013251417301268/v1_201708310023/en/main.assets" "Apartado" => array:4 [ "identificador" => "38706" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Editorial" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/20132514/0000003700000004/v1_201708310023/S2013251417301268/v1_201708310023/en/main.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2013251417301268?idApp=UINPBA000064" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 11 | 15 | 26 |
| 2024 October | 72 | 49 | 121 |
| 2024 September | 88 | 24 | 112 |
| 2024 August | 78 | 57 | 135 |
| 2024 July | 42 | 30 | 72 |
| 2024 June | 72 | 35 | 107 |
| 2024 May | 65 | 34 | 99 |
| 2024 April | 84 | 37 | 121 |
| 2024 March | 66 | 25 | 91 |
| 2024 February | 50 | 38 | 88 |
| 2024 January | 44 | 26 | 70 |
| 2023 December | 47 | 21 | 68 |
| 2023 November | 59 | 34 | 93 |
| 2023 October | 53 | 42 | 95 |
| 2023 September | 38 | 30 | 68 |
| 2023 August | 38 | 32 | 70 |
| 2023 July | 50 | 14 | 64 |
| 2023 June | 39 | 20 | 59 |
| 2023 May | 58 | 35 | 93 |
| 2023 April | 35 | 19 | 54 |
| 2023 March | 63 | 17 | 80 |
| 2023 February | 52 | 17 | 69 |
| 2023 January | 50 | 21 | 71 |
| 2022 December | 77 | 24 | 101 |
| 2022 November | 67 | 34 | 101 |
| 2022 October | 90 | 48 | 138 |
| 2022 September | 57 | 39 | 96 |
| 2022 August | 55 | 52 | 107 |
| 2022 July | 55 | 43 | 98 |
| 2022 June | 57 | 41 | 98 |
| 2022 May | 94 | 54 | 148 |
| 2022 April | 100 | 52 | 152 |
| 2022 March | 106 | 74 | 180 |
| 2022 February | 83 | 56 | 139 |
| 2022 January | 124 | 42 | 166 |
| 2021 December | 86 | 45 | 131 |
| 2021 November | 91 | 45 | 136 |
| 2021 October | 88 | 71 | 159 |
| 2021 September | 62 | 45 | 107 |
| 2021 August | 77 | 57 | 134 |
| 2021 July | 89 | 48 | 137 |
| 2021 June | 101 | 54 | 155 |
| 2021 May | 139 | 106 | 245 |
| 2021 April | 232 | 94 | 326 |
| 2021 March | 199 | 108 | 307 |
| 2021 February | 137 | 63 | 200 |
| 2021 January | 103 | 45 | 148 |
| 2020 December | 89 | 46 | 135 |
| 2020 November | 96 | 36 | 132 |
| 2020 October | 77 | 39 | 116 |
| 2020 September | 73 | 30 | 103 |
| 2020 August | 59 | 20 | 79 |
| 2020 July | 66 | 34 | 100 |
| 2020 June | 80 | 28 | 108 |
| 2020 May | 85 | 35 | 120 |
| 2020 April | 66 | 45 | 111 |
| 2020 March | 95 | 42 | 137 |
| 2020 February | 104 | 45 | 149 |
| 2020 January | 117 | 44 | 161 |
| 2019 December | 76 | 31 | 107 |
| 2019 November | 84 | 44 | 128 |
| 2019 October | 114 | 58 | 172 |
| 2019 September | 150 | 48 | 198 |
| 2019 August | 109 | 48 | 157 |
| 2019 July | 110 | 51 | 161 |
| 2019 June | 83 | 51 | 134 |
| 2019 May | 86 | 48 | 134 |
| 2019 April | 135 | 68 | 203 |
| 2019 March | 79 | 47 | 126 |
| 2019 February | 62 | 31 | 93 |
| 2019 January | 89 | 55 | 144 |
| 2018 December | 145 | 41 | 186 |
| 2018 November | 254 | 24 | 278 |
| 2018 October | 162 | 18 | 180 |
| 2018 September | 119 | 21 | 140 |
| 2018 August | 88 | 17 | 105 |
| 2018 July | 63 | 17 | 80 |
| 2018 June | 60 | 13 | 73 |
| 2018 May | 69 | 17 | 86 |
| 2018 April | 83 | 9 | 92 |
| 2018 March | 102 | 11 | 113 |
| 2018 February | 90 | 10 | 100 |
| 2018 January | 112 | 9 | 121 |
| 2017 December | 109 | 9 | 118 |
| 2017 November | 83 | 10 | 93 |
| 2017 October | 42 | 5 | 47 |
| 2017 September | 73 | 20 | 93 |
| 2017 August | 14 | 1 | 15 |
Show all
